Overview
Click Here to View the Program
Member fees will be applied to members of Forum for Innovative Regenerative Medicine (FIRM) as well as to DIA members. Please send the application form to DIA Japan office by fax or e-mail.
2nd DIA Cell Therapy Products Symposium in Japan
- End to End Development and Implementation: Steady Progress by Industry, Academia, and Government in Practical Use
The development of regenerative medicine in Japan, accelerated by new regulatory and legal systems that began to be scaled into practical use in 2013, has attracted considerable international attention. Currently, research has progressed to the point that many cell therapy products, both inside and outside Japan, are now entering clinical development, and this, in turn, has revealed a number of issues in product development, distribution, and post-marketing.
DIA Japan held its first Cell Therapy Products Symposium last year to bring together stakeholders, particularly from industry and academia, who were involved in developing cell therapy products. The mission was to share insights and exchange ideas with relevant government authorities in order to deepen mutual understanding and resolve issues of concern.
This year, the second Cell Therapy Products Symposium will focus on specific issues and challenges from the beginning of product development to post-marketing of domestic and overseas products, offering a platform for sharing experience and problem-solving efforts by leaders in academia and industry. Overseas trends and combination products with medical devices will be also reviewed. We hope for lively discussions on resolving these issues, and also on charting a direction for future development and business strategies that will be well harmonized internationally.
The DIA Cell Therapy Product Symposium encourages ongoing discussion across industry, academia, and government. We hope that this symposium will continue to grow as a place for sharing knowledge and insights about the latest product developments and as a highly valued networking opportunity for all participants. We look forward to your active participation.
Who should attend?
Program Committee
-
Yoji Sato, PhD • Head, Division of Cell-Based Therapeutic Products
National Institute of Health Sciences, Japan -
Yasuko Terao, PhD • Director, External Collaboration and Portfolio Management Department
Janssen Pharmaceutical K.K., Japan -
Teruyo Arato, PhD • Professor, Clinical Research and Medical Innovation Center
Hokkaido University Hospital, Japan -
Masaki Kasai, PhD • Principal Reviewer, Office of Cellular and Tissue-basaed Products
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Keiji Miyamoto • Principle, Regulatory Affairs Group, Post-Marketing Regulatory Affairs Dept.
Daiichi Sankyo Co., Ltd., Japan -
Sosuke Miyoshi, PhD •
Astellas Pharma Inc., Japan -
Hiromi Okabe, PhD • Manager, Global Regulatory Management Group, New Drug Regulatory Affairs Dept.
Daiichi Sankyo Co., Ltd., Japan -
Hideki Onimatsu, PhD • Manager, Regulatory CMC, Regulatory Affairs Department
Takeda Pharmaceutical Company Limited, Japan -
Kazuhiro Takekita • Instructor, Department of Cardiovascular Surgery, Graduate School of Medicine,
Osaka University, Japan -
Kouichi Tsuji • General Manager, Clinical Development Department
Terumo Corporation, Japan -
Yoshie Tsurumaki • Group Manager, Cell & Gene Franchise
Novartis Pharma K.K., Japan -
Akiko Ikeda, RPh • Senior Manager, Policy Intelligence Dept., Integrated Market Access Division
Janssen Pharmaceutical K.K., Japan
Contact us
Please contact the DIA Japan office in Tokyo for further information.
Tel: +81-3-6214-0574
Fax: +81-3-3278-1313
Japan@DIAglobal.org
www.diajapan.org